Nooka Ajay K, Kaufman Jonathan L, Rodriguez Cesar, Jakubowiak Andrzej, Efebera Yvonne, Reeves Brandi, Wildes Tanya, Holstein Sarah A, Anderson Larry D, Badros Ashraf, Shune Leyla, Chari Ajai, Pei Huiling, Cortoos Annelore, Patel Sharmila, Lin Thomas S, Richardson Paul G, Voorhees Peter
Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Future Oncol. 2022 Dec;18(40):4443-4456. doi: 10.2217/fon-2022-0775. Epub 2023 Feb 17.
WHAT IS THIS SUMMARY ABOUT?: This is a summary of a publication about Black participants of the GRIFFIN clinical study that was published in in April 2022. The GRIFFIN clinical study looked at the treatment combination of daratumumab plus a standard therapy for multiple myeloma (called RVd therapy, which stands for lenalidomide, bortezomib, and dexamethasone) in adult patients who had not been treated before for multiple myeloma and so were considered to have newly diagnosed multiply myeloma. Multiple myeloma is a blood cancer of plasma cells. Based on the participants' age, medical history, and indicators of good general health, the participants in the GRIFFIN study were also eligible to receive autologous stem cell transplant as part of their therapy. This summary describes results for the Black participants of the GRIFFIN clinical study who received daratumumab plus RVd therapy (called D-RVd) to see if D-RVd therapy is better than RVd therapy at reducing the amount of multiple myeloma cancer cells in a patient's body.
WHY DID THE RESEARCHERS EVALUATE THE RESULTS FOR BLACK PATIENTS IN THE GRIFFIN STUDY?: Due to racial disparities leading to historically low representation of minority groups in clinical studies, optimal treatments are not defined for Black patients with newly diagnosed multiple myeloma. Since previously published results from the overall population in the GRIFFIN study indicated that D-RVd therapy was better than RVd therapy, the researchers wanted to determine if this was also the case among Black participants.
WHAT WERE THE RESULTS?: Out of 207 participants in the GRIFFIN study, 15% (32 participants) were Black and 78% (161 participants) were White. In both Black and White participants, D-RVd therapy reduced the amount of myeloma cancer cells more than RVd therapy. Additionally, D-RVd and RVd therapy had similar safety results for Black and White participants.
WHAT DO THE RESULTS MEAN?: This analysis of GRIFFIN by race shows that Black people benefit from the daratumumab-containing D-RVd therapy as much as White people. Additionally, D-RVd therapy had similar safety results to RVd therapy for both Black and White people. : NCT02874742 (ClinicalTrials.gov).
本总结内容是什么？：这是一篇关于2022年4月发表的格里芬（GRIFFIN）临床研究中黑人参与者的出版物总结。格里芬临床研究观察了达雷妥尤单抗联合多发性骨髓瘤标准疗法（称为Rvd疗法，即来那度胺、硼替佐米和地塞米松）在之前未接受过多发性骨髓瘤治疗、因此被视为新诊断多发性骨髓瘤的成年患者中的应用。多发性骨髓瘤是一种浆细胞血癌。根据参与者的年龄、病史和良好总体健康指标，格里芬研究中的参与者也有资格接受自体干细胞移植作为其治疗的一部分。本总结描述了格里芬临床研究中接受达雷妥尤单抗联合Rvd疗法（称为D-Rvd）的黑人参与者的结果，以观察D-Rvd疗法在减少患者体内多发性骨髓瘤癌细胞数量方面是否优于Rvd疗法。
研究人员为何在格里芬研究中评估黑人患者的结果？：由于种族差异导致少数群体在临床研究中的代表性历来较低，新诊断的多发性骨髓瘤黑人患者的最佳治疗方法尚未确定。由于格里芬研究中先前公布的总体人群结果表明D-Rvd疗法优于Rvd疗法，研究人员想确定在黑人参与者中是否也是如此。
结果如何？：在格里芬研究的207名参与者中，15%（32名参与者）为黑人，78%（161名参与者）为白人。在黑人和白人参与者中，D-Rvd疗法比Rvd疗法更能减少骨髓瘤癌细胞数量。此外，D-Rvd和Rvd疗法在黑人和白人参与者中的安全性结果相似。
结果意味着什么？：这项按种族对格里芬研究的分析表明，黑人从含达雷妥尤单抗的D-Rvd疗法中获得的益处与白人一样多。此外，D-Rvd疗法在黑人和白人中的安全性结果与Rvd疗法相似。：NCT02874742（ClinicalTrials.gov）
